Novartis closes Avidity deal as rare heart disease spinout launches / Endpoints

Lei Lei Wu / endpoints - Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #healthcarefinance

Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions

10 days / medcitynews / Frank Vinluan

Novartis closes Avidity deal as rare heart disease spinout launches

12 days / endpoints / Lei Lei Wu

Monday, March 2, 2026, 12:23 am / permalink 19968 / 2 stories in 9 days

Related Stories

Servier to acquire Day One Biopharma for $2.5B / 4 days
Eli Lilly buys Orna to sprint into in‑vivo CAR‑T therapeutics / 25 days
Merck Eyes $30B Deal for Revolution Medicines Acquisition / 1 month
Merck acquires Cidara’s preventive flu drug for $9.2B / 3 months
Novartis pays $100M upfront for macrocyclic peptide platform / 18 days
Gilead to buy Arcellx for $7.8B, boosting cell therapy push / 15 days
Sanofi’s $2.2B Dynavax Acquisition Boosts Vaccine Portfolio / 2 months

Related Tags

Healthcare

Judge orders Leapfrog to remove safety grades for five Florida hospitals (21 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (40 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #healthcare

Pharmaceuticals

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

more #pharmaceuticals

Biotech

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

Cancer Grand Challenges awards five teams bold funding for cancer research (3 days)

Belzutifan combinations highlighted at ASCO GU improve RCC outcomes (4 days)

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.